Press Releases for MSFT

Press Releases
Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
Medarex to Present at the RBC Capital Markets Healthcare Conference
Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
Medarex Announces 2008 Third Quarter Financial Results
Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Medarex to Present at the UBS Global Life Sciences Conference
Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year
Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
Medarex to Present at the Thomas Weisel Partners Healthcare Conference
Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
Medarex Announces 2008 Second Quarter Financial Results
Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
Medarex Receives Milestone Payment for Acceptance of Investigational New Drug Application
BioWa and Medarex Announce License of BioWa's COMPLEGENT(TM) Technology
Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
Medarex Announces July 10 Live Webcast of R&D Day Event
Medarex to Present at the Jefferies Second Annual Healthcare Conference
Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of Clinical Oncology Annual Meeting
Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
Medarex Reports Phase 1 Clinical Data of MDX-1100 at Digestive Disease Week
Medarex Announces June 2nd Webcast Review and Discussion of Ipilimumab Data Presented at ASCO
BellwetherReport.com Analyst Report on IOMI, EMKR, GIGM and MEDX
Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Medarex Announces 2008 First Quarter Financial Results
Medarex to Present at the Bank of America 2008 Healthcare Conference
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
New Analyst Reports for BENCHMARK ENERGY CORP, MEDAREX INC, NEUROMETRIX INC, and INTEGRATED DEVICE TECHNOLOGY INC
Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
Medarex Reports Preclinical Data on Multiple Antibody-Drug Conjugate Candidates at American Association for Cancer Research Meeting
Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
Stocks Trading Report for Thursday! April 3, 2008
Medarex Announces Ipilimumab Program Continues to Move Forward
BellwetherReport.com Free Analyst Review for CTIC, MEDX, CROX and TSL